Last updated: June 10, 2026
Cancidas is the brand name of caspofungin acetate, a Candida-active echinocandin given as an IV infusion. Supplier mapping depends on (1) the specific market (US vs EU), (2) the commercial package strength, and (3) whether the supply chain refers to the sterile manufacturing site(s), the drug-substance source(s), or the commercial distribution network. With only the brand name “Cancidas” provided, a complete, accurate supplier list cannot be produced without drug-specific, jurisdiction-specific manufacturing and distribution data.
Who supplies Cancidas caspofungin acetate in the US market
Answer: Not determinable from the provided input.
What “supplier” means for Cancidas
Common interpretations that each change the supplier roster:
- Drug substance (caspofungin acetate) manufacturer(s)
- Sterile drug product manufacturer(s) for the lyophilized powder plus reconstitution and IV infusion setup
- Labeler/sponsor on FDA product listings
- Wholesale distributors and logistics partners
Which company manufactures Cancidas sterile drug product
Answer: Not determinable from the provided input.
Dosage forms and how they change the supplier set
Cancidas is supplied as a sterile IV formulation (lyophilized cake) that is reconstituted prior to infusion. Sterile fill-finish and aseptic packaging site(s) are often different entities than drug-substance suppliers.
What companies supply caspofungin acetate drug substance
Answer: Not determinable from the provided input.
Key supplier mapping points for caspofungin acetate
- Synthetic intermediate route suppliers
- API final-stage purification and salt-form conversion
- Quality agreements used by sterile drug-product manufacturers
What is the Orange Book status of Cancidas (and how it links to suppliers)
Answer: Not determinable from the provided input.
Why Orange Book data matters
For small-molecule brands, FDA listing often ties:
- NDA holder/labeler
- Patent holder(s)
- Manufacturer details (sometimes via application contacts and facility listings)
How strong is the patent estate for Cancidas and does it affect sourcing
Answer: Not determinable from the provided input.
Typical relevance to suppliers
Patent/OTC exclusivity timing can constrain who can supply:
- authorized generic manufacturers
- contract manufacturing organizations (CMOs) with rights to process
- generic entrants that displace the branded supply chain
What generic entry risks exist for caspofungin and change supplier dynamics
Answer: Not determinable from the provided input.
When supply changes typically accelerate
- After first approved generic launch
- After switching agreements between wholesalers and pharmacy benefit managers
- After contract re-tendering for sterile supply
What FDA regulatory pathway applies to Cancidas (NDA vs ANDA impacts sourcing)
Answer: Not determinable from the provided input.
Typical linkage
- Original NDA manufacturing is tied to branded labeler and application-defined facilities.
- ANDA manufacturers control their own CMOs and release testing for generics.
What litigation or settlements affect Cancidas supply
Answer: Not determinable from the provided input.
Why patent litigation affects suppliers
- Co-promotions or settlements can define manufacturing authorization.
- Design-around and process licensing can shift the supplier roster.
Commercial supply-chain questions: wholesale distributors of Cancidas
Answer: Not determinable from the provided input.
Distribution vs manufacturing
Wholesale distributors often differ from:
- NDA holder
- sterile CMOs
- API suppliers
Key Takeaways
- A complete and accurate “suppliers for Cancidas” list requires jurisdiction-specific manufacturing and distribution data tied to the exact marketed product.
- With only the brand name “Cancidas” provided, a definitive supplier roster for drug substance, sterile drug product, and distribution partners cannot be produced.
FAQs
- How do I identify the sterile manufacturing site for Cancidas in the US?
- Do caspofungin acetate drug-substance suppliers differ from Cancidas sterile fill-finish suppliers?
- How does FDA labeling (NDA holder vs manufacturer) change the supplier list for Cancidas?
- When generic caspofungin enters the market, how does it affect branded Cancidas supplier capacity?
- Which documents most reliably list Cancidas facility locations: FDA drug label, Orange Book, or inspection databases?
References (APA)
-
